Antiplatelet Chemoprevention of Occlusive Vascular Events and Death

UBC Faculty Research and Publications

Antiplatelet Chemoprevention of Occlusive Vascular Events and Death Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 37 summarizes the benefit and harm from taking four common antiplatelet drugs: acetylsalicylic acid, ticlopidine, clopidogrel and dipyridamole for prevention of cardiovascular events. Conclusions: For secondary prevention, ASA, 80 -325 mg/day, is proven effective for the prevention of vascular occlusive events for patients with established disease. There is little evidence of benefit beyond a maximum dose of ASA of 325 mg/day. Other antiplatelet drugs should be used for patients allergic to or intolerant of ASA. Patient characteristics, benefits, harm and cost should be considered when selecting an agent other than ASA. Combination of ASA with other antiplatelet agents requires further study.

Item Metadata

Title	Antiplatelet Chemoprevention of Occlusive Vascular Events and Death
Alternate Title	Therapeutics Letter 37
Creator	Therapeutics Initiative (University of British Columbia)
Date Issued	2000-10
Description	Therapeutics Letter 37 summarizes the benefit and harm from taking four common antiplatelet drugs: acetylsalicylic acid, ticlopidine, clopidogrel and dipyridamole for prevention of cardiovascular events. Conclusions: For secondary prevention, ASA, 80 -325 mg/day, is proven effective for the prevention of vascular occlusive events for patients with established disease. There is little evidence of benefit beyond a maximum dose of ASA of 325 mg/day. Other antiplatelet drugs should be used for patients allergic to or intolerant of ASA. Patient characteristics, benefits, harm and cost should be considered when selecting an agent other than ASA. Combination of ASA with other antiplatelet agents requires further study.
Subject	Aspirin; Clopidogrel; Dipyridamole; Platelet Aggregation Inhibitors; Ticlopidine
Genre	Other
Type	Text
Language	eng
Notes	The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available	2023-06-20
Provider	Vancouver : University of British Columbia Library
Rights	Attribution-NonCommercial-NoDerivatives 4.0 International
DOI	10.14288/1.0433616
URI	http://hdl.handle.net/2429/85026
Affiliation	Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status	Reviewed
Scholarly Level	Faculty; Researcher
Rights URI	http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository	DSpace

Open Collections

UBC Faculty Research and Publications